HF
CSTL icon

HRT Financial’s Castle Biosciences CSTL Stock Holding History

HRT Financial’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$389K Sell
15,858
-31,796
-67% -$1.04M ﹤0.01% 2699
2025
Q4 		$1.85M Buy
47,654
+415
+0.9% +$13.4K 0.01% 1355
2025
Q3 		$1.07M Buy
47,239
+28,413
+151% +$577K ﹤0.01% 1479
2025
Q2 		$384K Sell
18,826
-9,459
-33% -$175K ﹤0.01% 1730
2025
Q1 		$566K Buy
28,285
+15,916
+129% +$394K ﹤0.01% 1399
2024
Q4 		$329K Sell
12,369
-5,492
-31% -$167K ﹤0.01% 1668
2024
Q3 		$509K Buy
+17,861
New +$455K ﹤0.01% 1581
2024
Q2 		– Sell
-15,011
Closed -$332K – 2362
2024
Q1 		$332K Buy
+15,011
New +$327K ﹤0.01% 1495
2023
Q2 		– Sell
-15,008
Closed -$340K – 2591
2023
Q1 		$340K Buy
+15,008
New +$367K ﹤0.01% 1634
2022
Q4 		– Sell
-23,949
Closed -$624K – 2565
2022
Q3 		$624K Buy
+23,949
New +$671K 0.01% 1299
2021
Q4 		– Sell
-4,725
Closed -$314K – 3324
2021
Q3 		$314K Buy
+4,725
New +$332K ﹤0.01% 2374
2021
Q1 		– Sell
-8,821
Closed -$592K – 2754
2020
Q4 		$592K Buy
+8,821
New +$478K 0.01% 933

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HRT Financial's CSTL Position: Q1 2026 in Review

HRT Financial reduced its Castle Biosciences (CSTL) stake by 67% in Q1 2026, selling an estimated $1.04M and leaving 15,858 shares worth $389K. The position accounts for ﹤0.01% of the portfolio, ranked #2699.

HRT Financial first reported a position in CSTL in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.85M in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • HRT Financial held 15,858 shares of Castle Biosciences worth $389K as of Q1 2026.
  • HRT Financial sold 31,796 Castle Biosciences shares in Q1 2026, an estimated $1.04M.
  • Castle Biosciences made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #2699 holding.
  • HRT Financial first reported a position in Castle Biosciences in Q4 2020 and has held it in 12 quarters since.
  • HRT Financial's Castle Biosciences position peaked at $1.85M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.